RESTOR-MV: Randomized Evaluation of a Surgical Treatment for Off-Pump Repair of the Mitral Valve

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this prospective, randomized, multi-center, pivotal trial is to compare the safety and effectiveness of the off-pump, closed heart Coapsys System (Myocor, Inc.) to open surgical repair of the mitral valve using an annuloplasty ring or band in patients with moderate to severe functional mitral regurgitation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

MitraClip REPAIR MR Study

NCT04198870

Mitral Valve Regurgitation

ACTIVE_NOT_RECRUITING NA

Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure

NCT00608140

Mitral Valve Insufficiency Heart Failure

TERMINATED PHASE3

Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation

NCT01740583

Mitral Valve Regurgitation

UNKNOWN NA

Study on Safety and Performance of Medtentia Mitral Valve Repair System in Surgical Repair of Mitral Regurgitation

NCT01678144

Mitral Regurgitation Mitral Insufficiency

TERMINATED NA

Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial) and COAPT CAS

NCT01626079

Mitral Regurgitation Mitral Valve Regurgitation Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure Subjects +1 more

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patient clinical evaluations will consist of 3-month, 6-month, and 12-month follow up of the primary endpoints. Additional follow up of 18-month, 24-month, and annually thereafter will also be included.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mitral Valve Regurgitation Left Ventricular Dysfunction Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Less invasive mitral valve repair

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Grade 2, 3, or 4 functional mitral valve regurgitation per 2D echocardiography
* Patient undergoing concomitant coronary artery bypass graft surgery, either on-pump or off-pump
* Left ventricular ejection fraction greater than or equal to 25%
* Age between 18 and 80 years, inclusive
* Patient is willing and available to return for study follow up
* Ability of the patient or legal representative to understand and provide signed consent for participating in the study.

Exclusion Criteria

* Structural abnormality of the mitral valve (e.g. calcification or thickening of the valve leaflets, ruptured papillary muscle, ruptured chordae tendinae, mitral valve prolapse, mitral stenosis, etc.)
* Asymptomatic Grade 2 MR (those with NYHA Class \< II AND LVEF \> 40%)
* Organic valve disease resulting in insufficiency or stenosis of the aortic, pulmonary or tricuspid valve requiring surgical intervention
* Transmural myocardial infarction within 30 day period prior to surgical placement of Coapsys
* NYHA class IV
* Left ventricular end diastolic diameter \> 7.0 cm
* Cardiac surgery on an emergency or salvage basis
* Left atrial or left ventricular thrombus
* Left ventricular aneurysm
* Previous mitral valve surgery or other previous cardiac surgery that would preclude proper placement of the Coapsys
* Chronic renal failure requiring dialysis
* Open chest surgery contraindication (e.g., acute respiratory distress, endocarditis, myocarditis, pericarditis)
* Active infection
* Life expectancy of less than 24 months due to conditions other than their cardiac status
* Participation in another investigational drug or device protocol
* Abnormal coronary or cardiac anatomy such that the device could not be placed without interfering with those anatomical structures.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No